Suunto Race 3S: 38 Hours of Dual-Band GPS and a Paid AI Coach
Suunto Race 3S records 38 hours of dual-band GPS in a 56g watch, but costs $250 more than Race S and adds a paid AI Coach. What changed and who it fits.
Mito's $249 Heart Scan: What a Coronary Calcium Score Actually Tells You
Mito Health now offers a $249 coronary artery calcium scan, which shows existing arterial plaque. Who the 2026 ACC/AHA guidelines say should consider one.
Peptide Medicine's Gray Market Is Closing. Here's What Comes Next.
The gray-market peptide ecosystem — BPC-157, TB-500 — is formalizing under regulatory pressure. What that shift means for biohackers who depend on it.
The Longevity Biotech 100x Return Is Real — But It's Social Value, Not Investor Profit
A model puts $366.8 trillion of social value on therapies adding 10 years of life, against $3.3 trillion in costs. Why that 100x isn't an investor return.
Insilico Medicine's 287% Revenue Jump: AI Drug Discovery Is Becoming Real Pharma Revenue
Insilico Medicine grew to $106M revenue in H1 2026 on $7.3B in total deal value with Eli Lilly, Servier, and others — and a 90% gross margin that confirms AI drug pipelines have crossed from research promise to commercial scale.
Oura Health Files for IPO at $16 Billion: What a Smart Ring's Valuation Tells Us About Biometric Data
Oura Health is targeting a $3B raise at a $16B valuation — a 45% jump from 18 months ago — built on a hardware-plus-subscription model that turns sleep and recovery data into recurring revenue.
Mount Sinai's $1M XPRIZE Bet: Can the Immune System Be Reset to Fight Aging?
Mount Sinai secured $1M in XPRIZE Healthspan funding to run NYC-Vita, a trial combining lifestyle and medication to restore immune function decades lost to aging.
Quest Diagnostics Is Now Selling Biological Age: What the $29 Test Actually Measures
Humanity's biological age test is now a $29 add-on at 2,000 Quest locations. The model behind it tracked 306,000+ people for 11.6 years and covers six body systems.
Tru Niagen at GNC and Sam's Club Signals NAD+ Has Left the Longevity Niche
The number one NAD+ supplement in the US is now in nearly 300 retail locations across 44 states. What the GNC and Sam's Club expansion says about where the longevity market is heading.
Whole-Body MRI Is Leaving the Biohacker Bubble
EHE Health's partnership with Prenuvo brings whole-body MRI screening into 200+ preventive care clinics. What this transition from biohacker niche to medical infrastructure means for longevity-minded members.
Wonderfeel: What a 4,235% Growth Rate Signals for the NAD+ Supplement Market
The NAD+ longevity brand ranked No. 1 biotech on the 2026 Inc. 5000. The growth rate reflects a consumer longevity market that's moving faster than most industry observers expected.
Can AI Put the Cell Back Together? GenBio's Virtual Cell Model Tries
GenBio AI's AIDO Cell system creates a stateful virtual cell model — integrating DNA, RNA, and protein behavior — to predict how intervention sequences affect biological aging.
Function Health's AI Connector: Your Lab Results Just Became AI Training Data — For You
Function's new connector links 160+ personal lab results to ChatGPT, Claude, and Perplexity. Over 80% of members have at least one biomarker outside optimal range — now AI can reason over that directly.
Biological Age Clocks: The Regulatory Reckoning Is Coming
With $3.74 billion flowing into longevity biotech in Q1 2026 alone, investors are backing biological age diagnostics that regulators cannot yet validate. The collision between capital and clinical evidence is building.
The Antiaging Trial That Just Won $1M From XPRIZE to Test in Humans
AgelessRx has been selected as one of 10 Milestone 2 awardees in the $101M XPRIZE Healthspan competition, earning $1M to advance a one-year randomized trial testing a six-component antiaging protocol including low-dose rapamycin, NAD+, and metformin.
5 Perimenopause Supplements That Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are underdosed and opaque. This evidence-graded breakdown applies clinical trial dosing standards to the current field — here are the five that survive scrutiny.
Blood Filtering Is the New Wellness Flex — And Viome Just Bought the Infrastructure
Viome's acquisition of Circulate Health pairs multi-omics biomarker testing with therapeutic plasma exchange. What this convergence means for longevity-focused consumers navigating an increasingly clinical wellness stack.
Peptides: Peter Attia's Framework for Separating Science from Marketing
Peter Attia's episode #403 gives biohackers a rigorous 5-question test for evaluating peptides — and most gray-market compounds fail at question one.
Aging Research Has Been Studying the Wrong Sex
The Reproductive Resilience Hypothesis, published in Cell, argues female biology holds the key to understanding longevity — but most aging research has treated it as experimental noise.
One Shot, Five Organs: FGF21 Gene Therapy Extends Mouse Healthspan by 20%
A single AAV injection of FGF21 extended median lifespan by over 20% in aged mice, protecting liver, kidneys, heart, muscle, and brain — and it worked after age-related decline had already begun.
Human Longevity's $599 Genomics for All: What Clinical-Grade DNA Sequencing Gets You Now
Human Longevity sequences all 6.4 billion base pairs at $599 — and an AI layer re-alerts you as science evolves. What it covers, who it's actually for, and why the re-analysis matters more than the price.
The Bathroom as a Longevity Clinic: What Vivoo's Passive Monitoring Stack Changes
Vivoo's urinalysis platform and toilet-integrated hydration monitor embed daily biomarker collection into existing routines. What it covers, why passive beats active testing, and where this sits in a complete longevity stack.
NMR Blood Testing: One Blood Sample, Four Different Risk Scores
A single NMR blood scan reveals heart disease, insulin resistance, inflammation, and mortality risk — the inventor explains why one draw beats a standard panel.
Metabolic Health: Why GLP-1s Were Never the Whole Answer
GLP-1 drugs sparked the metabolic health boom, but the platforms building around it are betting the real product is what happens after the prescription.
Timeline Wins $5.3M Judgment Against Fake Urolithin A Sellers
A federal court awarded Timeline $5.3M and permanent injunctions against 19 counterfeit urolithin A sellers — a case that signals the longevity supplement market is finally getting real enforcement.
Fountain Life's $595 BASE Plan Is the Longevity Industry's Mass-Market Moment
Fountain Life's new BASE membership brings 100+ biomarkers, DEXA scan, and AI-guided clinician review to individuals for $595 — a significant shift from its ultra-premium roots.
Medtronic and Corsano Are Building the Hospital-to-Home Wearable Stack
Medtronic's integration of Corsano's FDA-cleared multi-parameter wearable into its HealthCast platform extends clinical monitoring from pre-op through home recovery — targeting alarm fatigue along the way.
SystemAge 2.1: The First Biological Age Test with Separate Male and Female Models
Generation Lab's SystemAge 2.1 analyzes 460+ biomarkers across 21 organ systems using gender-specific algorithms — the most granular biological age measurement now available through clinical partners.
GARM's Klotho Longevity Residency Brought 22 Participants to Honduras. Here's What They're Testing.
A four-day longevity residency at the Kimpton Grand Roatán included a proprietary Klotho intervention, blood sampling before and after, and researchers from MIT and Harvard. GARM is betting that Klotho is the next longevity biomarker to watch.
Rapalogix: $20M to Bring Rapamycin Anti-Aging Science to Skincare
Rapalogix Health raised a $20M Series A to expand rapamycin-based skincare targeting TORC1 — the cellular pathway behind systemic longevity interventions, now applied topically.
Menopause Tracking: Why the Average Is 9 Symptoms, Not 1 or 2
A Winona study of 100,000+ women found an average of nine simultaneous menopause symptoms — and 77.5% waited over a year before accessing care. The data reframes how practitioners should think about this life stage.
Your Complete Genome for $599: Human Longevity Inc. Bets on Consumer Genomics
Human Longevity Inc. now offers full whole-genome sequencing for $599 — down from ~$10,000 a decade ago — bundled with AI-powered multi-omics analysis across more than 50,000 conditions.
Beacon Biosignals: AI Sleep Staging Is Moving Out of the Lab
Beacon Biosignals presented clinical validation data for its AI sleep staging algorithms at SLEEP 2026. What their EEG foundation model means for where consumer sleep tech is headed.
Nuritas' AI-Discovered Peptides Are Now in Frozen Yogurt — and 31 Countries
Nuritas uses AI to discover functional peptides from plant proteins, then validates them through clinical research. At IFT FIRST 2026, PeptiStrong arrived in frozen yogurt format. What this means for functional nutrition.
Clair Raises $11.6M to Build the First Continuous Hormone Monitor for Women
Clair's wrist-worn device uses 10 biosensors and 130+ proprietary biomarkers to infer estrogen, progesterone, LH, and FSH levels in real time — revealing 9 distinct hormonal sub-phases the traditional 4-phase model misses.
Forever Chemicals Are Accelerating Your Biological Age — Longevity Needs to Catch Up
Two peer-reviewed studies link PFAS exposure to accelerated epigenetic aging via C-reactive protein. The longevity field's focus on what to add ignores what to remove — and that gap is measurable.
Geroscience Is Rewriting the Logic of Disease Prevention
Thirty percent of centenarians escape major age-related disease entirely — not by treating conditions as they arrive, but by aging differently. Geroscience targets the shared biological mechanisms underlying multiple diseases simultaneously. Here's where the clinical evidence stands in 2026.
The World's First Human Kidney Regeneration Surgery Is Scheduled for July 2026
Rokit Healthcare has clinical approval to begin the first human kidney regeneration trial using AI-assisted 3D bioprinting and robotic surgery with the patient's own omentum-derived cells — a milestone that sidesteps transplant waiting lists entirely.
China Launches the World's First 2,000-Person Stem Cell Antiaging Trial
Beijing's 301 Hospital is running the largest stem cell trial ever attempted for aging prevention, shifting longevity science from disease treatment toward systemic intervention.
Immorta Bio's Combination Therapy Reports 70%+ Lifespan Extension in Animal Models
A peer-reviewed study combining senolytic immunotherapy with stem cell regeneration shows dramatic lifespan gains. What the animal data does and doesn't tell us.
Biological Optionality: Why Freezing Your Younger Cells Now Is a Bet on Future Medicine
Acorn Biolabs harvests mesenchymal stem cells from hair follicles and cryopreserves them—banking the secretome of a healthier version of you against therapies that don't exist yet.
InsideTracker Pivots to AI Platform: What the Terra Shift Means for Biohacking
InsideTracker is becoming Terra, a B2B AI platform licensing biomarker-based health guidance to wellness and healthcare companies. The consumer brand isn't gone — it's becoming infrastructure.
Elysium Health Launches Physician-Led Longevity Program — Moving From Supplements to Clinical Care
Elysium's new Elysium Longevity Institute combines NAD+ protocols, peptides, and longitudinal data tracking under physician oversight. The shift signals a broader move in longevity from consumer supplementation to integrated clinical programs.
Wearables Are Writing Checks the FDA Can't Cash: The Regulatory Gap Getting Harder to Ignore
WHOOP earned $34.5M in federal backing. Apple Watch won an ECG clearance. And the FDA's framework for governing what these devices claim is still built for episodic care, not continuous monitoring.
Biohacking's Biggest Surprise: The Average Practitioner Is Over 65
The largest age group in biohacking is 65+, most practitioners spend under $500/month, and strength training beats peptide therapy 2:1.
Function Buys SuppCo: What Independent Supplement Testing Really Reveals
Function.health acquires SuppCo to add ISO-verified supplement testing to its 160-test biomarker platform. The backstory: roughly half of top-selling supplements fail their own label claims.
WHOOP Goes Clinical: What On-Demand Doctor Access Means for Your Recovery Data
WHOOP launches live clinician consultations on May 19 — the same day Fitbit rebrands to Google Health. What the parallel moves mean for serious health trackers.
Peptide Telehealth in 2026: The GLP-1 Distribution Model Reaches Longevity
LifespanningRx's partner program brings compounded peptide protocols to independent clinicians in 24 hours — the same telehealth model that mainstreamed GLP-1.
Niagen Plus: Why the NAD+ Market Just Went Injectable
Niagen Bioscience's $299 at-home injection kit delivers pharmaceutical-grade NR subcutaneously — bypassing gut metabolism. What the biohacking shift to injectables signals.
ŌURA's Acquisition Strategy: Building a Health AI Stack From Ring to Medical Records
Oura has acquired five companies since 2023 — gesture control, metabolic data, performance analytics, and now clinical records across 800+ healthcare systems. The pattern reveals a deliberate platform strategy.
60% of Workers Rank Health Access First. Employers Are Behind.
A new UK survey finds 60% of workers rank health insurance above all other benefits — a signal that healthspan is reshaping what employees expect from employers.
Portable Red Light Therapy Devices in 2026: A Tiered Buyer's Guide
The home RLT market hit $1.2B and is growing at 59% annually. What the numbers don't show: major capability gaps between $295 portable panels and $549 wearable devices.
ZEUGMA Hyperbaric Chamber: When HBOT Becomes a Longevity Engineering Tool
HPO.TECH's ZEUGMA chamber takes hyperbaric oxygen therapy from clinical setting to performance optimization — dissolving oxygen directly into plasma at 2.4 ATA for recovery and longevity.
Sleep: Top Health Priority, Lowest Follow-Through
ResMed surveyed 30,000 people across 13 countries: 84% know sleep extends healthy lifespan, but 53% get quality sleep only 4 nights a week. Wearable tracking tripled in one year.
NR Sales Hit $129M: What Niagen Bioscience's 30% Growth Signals About the NAD+ Market
Niagen Bioscience reported $129.4M in 2025 revenue — up 30% — with net income more than doubling. The NAD+ precursor category is no longer a niche bet.
Sensory Stimulation Architecture: Cognito's $105M Cognitive Longevity Play
Cognito Therapeutics secures $105M to advance its non-invasive sensory stimulation therapy, marking a shift in Alzheimer's treatment architecture from chemical to electrical intervention.
Biohacking Data Sovereignty: Owning Your Biological Identity
Why the future of biohacking depends on decentralized data storage and the elimination of centralized health platforms.
The Industrialization of Longevity: Clinical Rigor and the End of Biohacking Hype
Analyzing the transition from experimental biohacking to clinical validation, driven by ARPA-H funding and new FDA regulatory frameworks.
The Industrialization of Personal Biology: Beyond the Quantified Self
How biohacking is shifting from hobbyist self-experimentation to a rigorous data-driven industry.